Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.

Trial Details

NCT ID

NCT06522919

Phase

PHASE2

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Autologous Dendritic Cell (DC) Vaccine

Locations (sample)

Meldola, Forlì Cesena, Italy|44.12775,12.0626
Tricase, Lecce, Italy|39.93018,18.35421

Key Eligibility Criteria

Be willing and able to provide written informed consent.
Histologically confirmed pMMR or MSS mCRC
Male or female, aged ≥ 18 years
Life expectancy greater than 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →